Volume 0 - Int J Mol Cell Med (In Progress)                   Int J Mol Cell Med 2025, 0 - Int J Mol Cell Med (In Progress): 0-0 | Back to browse issues page

XML Print

Download citation:
BibTeX | RIS | EndNote | Medlars | ProCite | Reference Manager | RefWorks
Send citation to:
Azizi R, Ahmed H H, l Kareem R A, Taher Waam W M, Alwan M, Jasem Jawad M, et al . SLC7A11 Inhibitors Represent a Promising Therapeutic Target by Facilitating the Induction of Ferroptosis in Breast Cancer. Int J Mol Cell Med 2025;
URL: http://ijmcmed.org/article-1-2440-en.html
SLC7A11 Inhibitors Represent a Promising Therapeutic Target by Facilitating the Induction of Ferroptosis in Breast Cancer
Rojin Azizi1 , Hanan Hassan Ahmed2 , Radhwan Abdu L Kareem3 , Waam mohammed Taher Waam4 , Mariem Alwan5 , Mahmood Jasem Jawad6 , Atheer Khdyair Hamad7 , Satinik Darzi 8
1- Master in Molecular and Cellular Biology in Department of Science at Islamic Azad University, Yadegar Emam Branch Tehran, Iran.
2- College of Pharmacy, Alnoor University, Mosul, Iraq.
3- Ahl Al Bayt University Kerbala, Iraq.
4- 4College of Nursing, National University of Science and Technology, Dhi Qar, Iraq
5- Pharmacy college, Al-Farahidi University, Iraq.
6- Department of Pharmacy, Al-Zahrawi University College, Karbala, Iraq.
7- Gilgamesh Ahliya University, Baghdad, Iraq.
8- Abnormal Uterine Bleeding Research Center, Semnan University of Medical Sciences Semnan, Iran. , Sati.darzi@gmail.com
Abstract:   (314 Views)
It is predicted with near certainty that an estimated 310,720 women will be diagnosed with invasive breast carcinoma in 2024, while the number of men will be significantly lower at around 2,800, highlighting the alarming prevalence of this cancer across the sexes. The Solute Carrier Family 7 Member 11(SLC7A11) gene is vital for the exchange of extracellular cystine for glutamate at a 1:1 ratio and its expression is significantly increased in various tumors. Numerous research studies have shown that SLC7A11 expression is fine-tuned at several levels, contributing to its pharmacological functions in tumors, such as maintaining cellular redox balance, promoting cell proliferation, and influencing ferroptosis. Many studies suggest that reducing SLC7A11 expression and activity may be beneficial for cancer treatment, making it a promising target for therapy. However, recent findings also suggest that inhibiting SLC7A11 in certain scenarios may increase the survival of cancer cells and promote drug resistance. This review begins with a brief overview of the properties of SLC7A11, including its structural features and physiological functions, followed by a summary of its potential regulators. We then delve deeper into its role in cancer, particularly breast cancer, and explore the relationships between SLC7A11 and ferroptosis, proliferation, metastasis, and therapeutic resistance. Consequently, more customized therapeutic approaches should be considered when targeting SLC7A11 in the context of breast cancer. Thus, high expression of SLC7A11 is associated with poor prognosis in breast cancer, and various inhibitors have been identified that can effectively target this transporter. Innovative therapeutic strategies, including immunotherapies targeting SLC7A11, can potentially reduce tumor growth and metastasis in breast cancer models.
Keywords: SLC7A11, tumor, breast cancer, ferroptosis, therapeutic resistance, inhibitors
Full-Text [PDF 518 kb]   (171 Downloads)    
Type of Study: Review | Subject: Cancer
Received: 2024/09/28 | Accepted: 2024/10/23 | Published: 2025/01/5
Add your comments about this article : Your username or Email:
CAPTCHA
Send email to the article author

Rights and permissions
Creative Commons License This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

© 2025 CC BY-NC 4.0 | International Journal of Molecular and Cellular Medicine IJMCM

Designed & Developed by : Yektaweb